Last reviewed · How we verify

Rosiglitazone and Pegasys/Ribavirin

Beth Israel Medical Center · FDA-approved active Small molecule

Rosiglitazone and Pegasys/Ribavirin is a Thiazolidinedione (rosiglitazone) combined with pegylated interferon alfa-2a and nucleoside analog (ribavirin) Small molecule drug developed by Beth Israel Medical Center. It is currently FDA-approved for Type 2 diabetes mellitus in patients with chronic hepatitis C infection.

This combination uses rosiglitazone to improve insulin sensitivity in diabetic patients while pegasys/ribavirin acts as an antiviral therapy for hepatitis C infection.

This combination uses rosiglitazone to improve insulin sensitivity in diabetic patients while pegasys/ribavirin acts as an antiviral therapy for hepatitis C infection. Used for Type 2 diabetes mellitus in patients with chronic hepatitis C infection.

At a glance

Generic nameRosiglitazone and Pegasys/Ribavirin
SponsorBeth Israel Medical Center
Drug classThiazolidinedione (rosiglitazone) combined with pegylated interferon alfa-2a and nucleoside analog (ribavirin)
TargetPPAR-γ (rosiglitazone); Interferon-α receptor and HCV NS5B polymerase (pegasys/ribavirin)
ModalitySmall molecule
Therapeutic areaEndocrinology/Diabetes and Virology/Hepatology
PhaseFDA-approved

Mechanism of action

Rosiglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to enhance insulin sensitivity and reduce hepatic glucose production. Pegasys (peginterferon alfa-2a) combined with ribavirin provides antiviral activity against hepatitis C virus through interferon-mediated immune activation and ribavirin's direct antiviral effects. This combination addresses concurrent type 2 diabetes and chronic hepatitis C infection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Rosiglitazone and Pegasys/Ribavirin

What is Rosiglitazone and Pegasys/Ribavirin?

Rosiglitazone and Pegasys/Ribavirin is a Thiazolidinedione (rosiglitazone) combined with pegylated interferon alfa-2a and nucleoside analog (ribavirin) drug developed by Beth Israel Medical Center, indicated for Type 2 diabetes mellitus in patients with chronic hepatitis C infection.

How does Rosiglitazone and Pegasys/Ribavirin work?

This combination uses rosiglitazone to improve insulin sensitivity in diabetic patients while pegasys/ribavirin acts as an antiviral therapy for hepatitis C infection.

What is Rosiglitazone and Pegasys/Ribavirin used for?

Rosiglitazone and Pegasys/Ribavirin is indicated for Type 2 diabetes mellitus in patients with chronic hepatitis C infection.

Who makes Rosiglitazone and Pegasys/Ribavirin?

Rosiglitazone and Pegasys/Ribavirin is developed and marketed by Beth Israel Medical Center (see full Beth Israel Medical Center pipeline at /company/beth-israel-medical-center).

What drug class is Rosiglitazone and Pegasys/Ribavirin in?

Rosiglitazone and Pegasys/Ribavirin belongs to the Thiazolidinedione (rosiglitazone) combined with pegylated interferon alfa-2a and nucleoside analog (ribavirin) class. See all Thiazolidinedione (rosiglitazone) combined with pegylated interferon alfa-2a and nucleoside analog (ribavirin) drugs at /class/thiazolidinedione-rosiglitazone-combined-with-pegylated-interferon-alfa-2a-and-nucleoside-analog-ribavirin.

What development phase is Rosiglitazone and Pegasys/Ribavirin in?

Rosiglitazone and Pegasys/Ribavirin is FDA-approved (marketed).

What are the side effects of Rosiglitazone and Pegasys/Ribavirin?

Common side effects of Rosiglitazone and Pegasys/Ribavirin include Fluid retention and edema, Weight gain, Anemia, Fatigue, Flu-like symptoms, Hepatotoxicity.

What does Rosiglitazone and Pegasys/Ribavirin target?

Rosiglitazone and Pegasys/Ribavirin targets PPAR-γ (rosiglitazone); Interferon-α receptor and HCV NS5B polymerase (pegasys/ribavirin) and is a Thiazolidinedione (rosiglitazone) combined with pegylated interferon alfa-2a and nucleoside analog (ribavirin).

Related